How The Investment Story Is Shifting For Halozyme Therapeutics (HALO) After Recent Analyst Calls [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Analysts have shifted their price targets for Halozyme Therapeutics into a US$75 to US$90 range, even as the model fair value estimate holds steady at US$84.5. The higher end of that range is linked by some firms to recent Q4 results and expectations for royalty revenues tied to ENHANZE partnerships, while the US$75 target highlights that not every research desk views the setup in the same way. As you read on, you will see how these differing calls fit into the evolving story around Halozyme and what to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Halozyme Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Morgan Stanley recently lifted its Halozyme price target to US$94 from US$78 after what it called strong Q4 results, highlighting royalty revenues, expanding ENHANZE partnerships, and progress with Hypercon and Surf Bio assets. Benchmark raised its target to US$90 from US$
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]Yahoo! Finance
- Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial OfficerPR Newswire
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 3/27/26 - Form SCHEDULE
- HALO's page on the SEC website